Patients who undergo thoracic aortic surgery
Conditions
Interventions
Arm1: liberal strategy Platelet concentrates are transfused if the platelet count drops below 100,000/uL,and platelet counts are maintained at 100,000/uLor more. Cryoprecipitates are transfused if p
Sponsors
National Cardiovascular Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient must be scheduled to undergo thoracic aortic surgery Patient must be >=20 years and <90 years of age Patient must be willing and able to give informed consent (or written informed consent is obtained from the patient's legal representative in case in which informed consent could not be obtained from the patient because of critical illness.)
Exclusion criteria
Exclusion criteria: The Patient has a congenital bleeding tendency The patient has chronic thrombocytopenia (defined as a platelet count <100,000/uL for more than 30 days) The patient has anemia (defined as a hemoglobin level <8.0g/dL) The patient possesses an anti-HLA or anti-platelet antibody, resulting in platelet refractoriness It is highly possible to complete the surgery of the patient without any transfusion in the judgement of the investigator. The patient is inappropriate for entry onto this study in the judgment of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main outcome measures: The total volume of allogeneic red blood cells transfused during the surgery and within 24 hours after the surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Other outcome measures: The total volume of mediastinal drainage during the first 12 hours or the first 24 hours in the ICU, re-exploration for bleeding, duration of time in the operating room after CPB, length of stay in ICU and hospital, hospital death, one-year survival, morbidity (e.g., renal failure, liver dysfunction, infection, heart failure, MI, neurological dysfunction, thromboembolic events), the total amount of each blood component transfused during hospitalization, the value of hemoglobin, platelet count, fibrinogen, prothrombin time, or activated partial thromboplastin time just prior to transfusion of each blood component, and the total medical cost. | — |
Countries
Japan
Contacts
Public ContactHitoshi Ogino
National Cardiovascular Center Department of Cardiovascular Surgery
Outcome results
None listed